
Danny Wolin appointed as KJT’s Senior VP of real-world evidence
Ella Day | September 11, 2025 | Appointment | Medical Communications, Research and Development | KJT, real-world evidence
Danny Wolin has been appointed as Senior Vice President of Real-World Evidence at KJT.
KJT is an evidence-based healthcare consulting firm focused on strategic research insights, real-world evidence and medical communications for healthcare organisations.
Danny is an observational research scientist with extensive cross-functional experience in the pharmaceutical industry. He has a proven track record of designing and leading complex qualitative and quantitative real-world evidence (RWE) studies that inform impactful healthcare decisions to identify unmet patient needs.
Michaela Gascon, CEO of KJT, said: “Danny brings decades of critical expertise that will transform our approach to patient-centred research. His deep understanding of regulatory landscapes and proven track record in real-world evidence will be instrumental in accelerating our strategic growth and delivering meaningful insights that can directly impact patient outcomes.”
Danny commented: “I am passionate about and deeply committed to patient-centred research, with direct experience engaging patients and their caregivers to ensure that new therapies and approaches to care reach those who need them most.”
KJT is dedicated to fostering innovation and delivering exceptional value to its stakeholders. The addition of Danny Wolin underscores the company’s commitment to building a world-class leadership team poised to achieve strategic objectives and deliver sustained success.

This article featured in: October 2025 – The Pharmafile Brief
Related Content

Reinventing the value equation
There is a duty to ensure access to innovative treatments for patients with unmet need, …

Protecting public health: Is real-world evidence the key?
In often tough regulatory climates and with threats to public health are growing in sceptical …

FDA turns to real-world evidence to improve regulatory process
The FDA has announced its intention to incorporate real-world data elements to a greater degree …






